Table 4.

The HBV therapeutic development landscape as of 2019.

	Target/strategy	Preclinical	Human Phase trials
DDA	Entry		Myrcludex B (MyrB)
	DNA pol		Tenofovir exalidex, CMX-157, hexadecyloxypropyl-tenofovir (Contravir Pharmaceuticals) − TAF (GS) − Clevudine (Korea)
	siRNA/antisense	Ben BBHB 331 − DCR HBs − RG6004 − LunarHBV Janssen	ARO HBV RNAi − Aln Vir HBV − ARB 467 RNAi − IONIS − HBV − LRx IONIS − HBVRx
	sAg	BSBI edi2 − BSBI 259 sAg − TTP sAg	REP 2139 − REP 2165*
	Capsid	Benza capsid − CpAMS capsid	AB 423 capsid − ABI H2158 − ABI H0731 − RG7907 − AB 503 − QL 007 − RG7048 − GLS − 4 HEC − ABI 7031 − J&J 6379
	RNA destabilizers	EBT 106 − Roche DHQ − AB 452
	cccDNA	CRISPCAS (intel)ia − CRIPR CoCrystal − BSBI (Jt Guo)	ALN-HBV − ARB-1467 − ARC RNAi
Host	Non immunomodulators	EYP001 FXR Enyo − GS 5801 [inhibitor of histone demethylase (lysine demethylase 5 (KDM5)]	EYP001 − Lonafarnib* EI
	Innate Immune modulators	GS 9688 (TLR 8 agonist)	SB 9200 (RIG 1+, di-nuc) − Poly IC (interferon pathway) − HBV inf den cells (Ag presentation) − Inarigivir (RIG I/STING) − GS-9620 (vesatolimod - TLR 7 agonist) − Nivolumab (anti-PD-1)
	Adaptive immune modulators/vaccines	Imm TAV TCR IC − Tomega Vax − MVA-VIP GV	CVIHBV002 − ABX203 − Ino 1800 − DV601 − HB110 Ichor − INO 1800 − TG 1050 − IFN + IL2 + vaccine

AB, ARB: Arbutus; ABI, Aln, Alnylam; Alt, Altimmune; Apg, Ascentage; BSBI, Blumberg; Ben, Benitech; DCR, Dicerna; EBT, Excision; EI, Eiger, EY, Enyo, GS, Gilead; INO, Innovio; Rep, Replicor; GV, Genvax; GSK, Glaxo; IC, Immunocore; RG, Roche; SB, Springbank; TG, Transgene.